title: Paroxetine mesylate: comparable to paroxetine hydrochloride?
abstract: BACKGROUND
  Currently available small case reports clearly propose that existing regulatory procedures to approve generic versions only require essential bioequivalence, have limitations and fail to meet stricter scientific and clinical demands.
  
  
  METHODS
  Data indicate that paroxetine mesylate has some potential differences in bio- and clinical equivalence compared with paroxetine hydrochloride, although it has not been fully and sufficiently investigated in well-designed clinical trials. Data available now regarding safety, tolerability, efficacy and practical issues dealing with debates between generic and brand-name products paroxetine mesylate and paroxetine hydrochloride are presented in the review.
  
  
  RESULTS
  Preclinical and clinical data are reviewed, and clinical issues relating to use of generic version versus original product are comprehensively discussed; tips for the clinician in clinical practice are also provided.
  
  
  CONCLUSIONS
  Potential differences in efficacy and safety but also reduction in the use of health care and in pharmacy cost should be considered when choosing the generic version or the original product based on the clear benefit-risk ratio in patients.
authors.affiliation: The Catholic University of Korea College of Medicine, Bucheon St Mary's Hospital, Department of Psychiatry, 2 Sosa-Dong, Wonmi-Gu, Bucheon Kyounggi-Do 420-717, South Korea. pae@catholic.ac.kr
authors.forename: Chi-Un
authors.initials: CU
authors.lastname: Pae
authors.forename: Aayushman
authors.initials: A
authors.lastname: Misra
authors.forename: Byung-Joo
authors.initials: BJ
authors.lastname: Ham
authors.forename: Changsu
authors.initials: C
authors.lastname: Han
authors.forename: Ashwin A
authors.initials: AA
authors.lastname: Patkar
authors.forename: Prakash S
authors.initials: PS
authors.lastname: Masand
mesh_terms: D003257:Consumer Product Safety; D017281:Cost of Illness; D017277:Drug Approval / Q000191:economics / Q000379:methods*; D006801:Humans; D017374:Paroxetine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D017374:Paroxetine